Tenaya Therapeutics (TNYA) Expected to Announce Quarterly Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) is expected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Tenaya Therapeutics to post earnings of ($0.12) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:00 PM ET.

Tenaya Therapeutics Trading Down 7.8%

Tenaya Therapeutics stock opened at $0.56 on Monday. The business’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $1.14. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $2.35. The company has a market cap of $91.99 million, a price-to-earnings ratio of -0.72 and a beta of 3.22.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TNYA shares. Canaccord Genuity Group dropped their price target on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Chardan Capital dropped their price objective on shares of Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Wednesday, January 21st. HC Wainwright lowered their price target on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, December 12th. Finally, Morgan Stanley set a $2.00 price target on shares of Tenaya Therapeutics in a research note on Thursday, January 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.50.

Insider Buying and Selling at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total value of $1,966,622.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 8,594,047 shares of company stock worth $5,430,207 in the last quarter. Corporate insiders own 48.65% of the company’s stock.

Institutional Trading of Tenaya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC bought a new stake in Tenaya Therapeutics during the first quarter valued at $442,000. Jane Street Group LLC increased its stake in Tenaya Therapeutics by 1,958.7% in the 2nd quarter. Jane Street Group LLC now owns 376,068 shares of the company’s stock worth $230,000 after acquiring an additional 357,801 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Tenaya Therapeutics in the 4th quarter valued at about $168,000. Bridgeway Capital Management LLC boosted its position in shares of Tenaya Therapeutics by 883.8% during the 4th quarter. Bridgeway Capital Management LLC now owns 194,800 shares of the company’s stock valued at $139,000 after acquiring an additional 175,000 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Tenaya Therapeutics by 18,500,000.0% during the 4th quarter. Barclays PLC now owns 185,001 shares of the company’s stock valued at $132,000 after acquiring an additional 185,000 shares during the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.